Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Pharmacists Ban Sales Of Combo Drugs With Safety Issues (India)

This article was originally published in PharmAsia News

Executive Summary

Despite a court stay against a proposed government ban on combination drugs, most of India's retail pharmacists plan to refuse to sell them. The All India Organization of Chemists and Druggists, which represents two-thirds of pharmacists in India, said it was following a directive of the regulatory authority to withdraw licenses of combination drugs that failed to comply with quality standards. The drugs, which account for more than 10 percent of retail pharmacy drug sales in the country, had been approved without having undergone proper quality-safety tests. Regulators count 186 new applications for the combinations that involve combining two or more already-approved drugs into a single formulation, and 50 of them have been rejected so far because of inadequate proof of quality and efficacy. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel